These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18793028)

  • 1. Trastuzumab in early-stage breast cancer: the question of treatment timing.
    Simoens S
    Pharmacoeconomics; 2008; 26(10):807-9. PubMed ID: 18793028
    [No Abstract]   [Full Text] [Related]  

  • 2. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial.
    Purmonen TT; Pänkäläinen E; Turunen JH; Asseburg C; Martikainen JA
    Acta Oncol; 2011 Apr; 50(3):344-52. PubMed ID: 21299447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer.
    Tran PT; Diaby V
    J Manag Care Spec Pharm; 2020 Feb; 26(2):221. PubMed ID: 32011959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
    Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
    J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab before breast surgery: is concurrent administration with anthracycline-containing chemotherapy necessary?
    Del Mastro L; Bighin C; Bini G; Giraudi S; Taveggia P; Levaggi A; Canavese G; Rescinito G; Pronzato P
    Ann Oncol; 2010 Jun; 21(6):1376-1377. PubMed ID: 20430904
    [No Abstract]   [Full Text] [Related]  

  • 6. Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer.
    Metro G; Giannarelli D; Gemma D; Lanzetta G; Ciccarese M; Papaldo P; Gamucci T; Lorusso V; Mottolese M; Magnolfi E; Cognetti F; Fabi A
    Breast J; 2010; 16(1):66-72. PubMed ID: 19889170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis.
    Poncet B; Bachelot T; Colin C; Ganne C; Jaisson-Hot I; Orfeuvre H; Peaud PY; Jacquin JP; Salles B; Tigaud JD; Mechin-Cretinon I; Marechal F; Fournel C; Trillet-Lenoir V
    Am J Clin Oncol; 2008 Aug; 31(4):363-8. PubMed ID: 18845995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compassionate use of humanized anti-HER2/neu protein, trastuzumab for metastatic breast cancer in Japan.
    Tokuda Y; Suzuki Y; Ohta M; Saito Y; Kubota M; Tajima T; Umemura S; Osamura RY
    Breast Cancer; 2001; 8(4):310-5. PubMed ID: 11791123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer.
    Metcalfe S; Evans J; Priest G
    N Z Med J; 2007 Jun; 120(1256):U2593. PubMed ID: 17589560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant combination for stage II-III breast cancer.
    Bagchi S
    Lancet Oncol; 2007 Jul; 8(7):579. PubMed ID: 17668486
    [No Abstract]   [Full Text] [Related]  

  • 12. A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2).
    Moulder SL; Arteaga CL
    Clin Breast Cancer; 2003 Jun; 4(2):142-5. PubMed ID: 12864943
    [No Abstract]   [Full Text] [Related]  

  • 13. Dual-agent molecular targeting of the ErbB2 receptor: killing one bird with two stones.
    Hirte HW; Hotte SJ
    J Clin Oncol; 2008 Jul; 26(20):3301-2. PubMed ID: 18490647
    [No Abstract]   [Full Text] [Related]  

  • 14. Bevacizumab for advanced breast cancer: all tied up with a RIBBON?
    Burstein HJ
    J Clin Oncol; 2011 Apr; 29(10):1232-5. PubMed ID: 21383305
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
    Ardavanis A; Tryfonopoulos D; Orfanos G; Karamouzis M; Scorilas A; Alexopoulos A; Rigatos G
    Onkologie; 2005 Nov; 28(11):558-64. PubMed ID: 16249641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.
    Elkin EB; Weinstein MC; Winer EP; Kuntz KM; Schnitt SJ; Weeks JC
    J Clin Oncol; 2004 Mar; 22(5):854-63. PubMed ID: 14990641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis.
    Nerich V; Chelly J; Montcuquet P; Chaigneau L; Villanueva C; Fiteni F; Meneveau N; Perrin S; Voidey A; Monnot T; Pivot X; Limat S
    J Oncol Pharm Pract; 2014 Oct; 20(5):362-8. PubMed ID: 24158979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer.
    Lidgren M; Wilking N; Jönsson B; Rehnberg C
    Acta Oncol; 2008; 47(6):1018-28. PubMed ID: 18607881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab and breast cancer. Are we just beyond the prologue of a fascinating story?
    Puglisi F; Piccart M
    Onkologie; 2005 Nov; 28(11):547-9. PubMed ID: 16249638
    [No Abstract]   [Full Text] [Related]  

  • 20. Dose-dense chemotherapy with trastuzumab is an appropriate option.
    Dang C; Norton L; Hudis C
    J Clin Oncol; 2008 Jul; 26(21):3655-6; author reply 3656. PubMed ID: 18640949
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.